Trial Profile

A longitudinal, observational, multicenter study assessing patient dosing and satisfaction after switching to Rurioctocog Alfa Pegol

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 30 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emicizumab (Primary) ; Rurioctocog alfa pegol (Primary)
Indications Haemophilia A
Focus Therapeutic Use
Acronyms ATHN 2

Most Recent Events

14 Dec 2021 Results from the Athn 2 Study presented at the 63rd American Society of Hematology Annual Meeting and Exposition
03 Feb 2021 According to a Takeda media release, data from this study are being presented at the Virtual European Association for Haemophilia and Allied Disorders Congress (EAHAD 2021).
06 Jan 2021 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com